Skip to main content

Table 1 Summary of cases with ECMO of myocarditis from immune checkpoint inhibitors.

From: Fulminant myocarditis induced by immune checkpoint inhibitor nivolumab: a case report and review of the literature

Authors, year

Age, sex

Malignancy

ICI

Doses prior to myocarditis

Treatments utilized

Outcome

Arangalage et al. (2017)

35, F

Melanoma

Ipi 3 mg/kg,

Nivo 1 mg/kg

1

Intravenous solumedrol 1 g/day and IVIG followed by ECMO and plasma exchange followed by tacrolimus

Survived

Frigeri et al. (2018)

76, F

Metastatic

lung adenocarcinoma

Nivo

(dose NA)

7

ECMO, IABP, intravenous methylprednisolone 5 mg/kg/day, plasmapheresis, infliximab

5 mg/kg, three doses

Survived

Yamaguchi et al. (2018)

60, M

Melanoma

Nivo

2 mg/kg

13

ECMO, IABP, intravenous prednisolone 1000 mg/day for 3 days + IVIG at 50 g/day for 2 days

Survived

Imai et al. (2018)

70, M

Squamous cell carcinoma of lung

Pembro

(200 mg)

2

Intravenous methylprednisolone (1 g/day) for 3 days, IVIG 1 g/kg for 2 days, ECMO, IABP

Died

  1. ECMO extracorporeal membrane oxygenation, ICI immune checkpoint inhibitors, IABP intraaortic balloon pump, IVIG intravenous immunoglobulin, ipi ipilimumab, nivo nivolumab, pembro pembrolizumab, mg/kg milligrams/kilogram body weight, NA not available